Mechanism of isochlorogenic acid A against hepatocellular carcinoma based on PI3K/Akt/mTOR signaling pathway combined with multi-omics

SU Weiwei; JIA Weibing; REN Houjian; SU Xianhui; GAO Huijie; HUO Zhongchao; HOU Xin; WANG Zhen

doi:10.6039/j.issn.1001-0408.2026.10.04

您当前的位置：

首页 >

文章列表页 >

Mechanism of isochlorogenic acid A against hepatocellular carcinoma based on PI3K/Akt/mTOR signaling pathway combined with multi-omics

更新时间：2026-05-26

- Mechanism of isochlorogenic acid A against hepatocellular carcinoma based on PI3K/Akt/mTOR signaling pathway combined with multi-omics
- ZHONGGUO YAOFANG Vol. 37, Issue 10, Pages: 1258-1263(2026)
- 作者机构：
  
  1.河北工程大学临床医学院，河北邯郸　056000
  2.邯郸市中心医院全科医学科，河北邯郸　056000
  3.河北工程大学医学院，河北邯郸　056000
  4.河北工程大学附属医院肿瘤科，河北邯郸　056000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.10.04
  CLC： R965
- Received：14 November 2025，
  
  Revised：2026-05-12，
  
  Accepted：15 May 2026，
  
  Published：30 May 2026
- 稿件说明：
移动端阅览
苏巍巍,贾卫兵,任厚健,等.基于PI3K/Akt/mTOR信号通路联合多组学探讨异绿原酸A抗肝癌的作用机制 ^Δ[J].中国药房,2026,37(10):1258-1263. DOI: 10.6039/j.issn.1001-0408.2026.10.04.

SU Weiwei,JIA Weibing,REN Houjian,et al.Mechanism of isochlorogenic acid A against hepatocellular carcinoma based on PI3K/Akt/mTOR signaling pathway combined with multi-omics[J].ZHONGGUO YAOFANG,2026,37(10):1258-1263.
苏巍巍,贾卫兵,任厚健,等.基于PI3K/Akt/mTOR信号通路联合多组学探讨异绿原酸A抗肝癌的作用机制 ^Δ[J].中国药房,2026,37(10):1258-1263. DOI: 10.6039/j.issn.1001-0408.2026.10.04. DOI：

SU Weiwei,JIA Weibing,REN Houjian,et al.Mechanism of isochlorogenic acid A against hepatocellular carcinoma based on PI3K/Akt/mTOR signaling pathway combined with multi-omics[J].ZHONGGUO YAOFANG,2026,37(10):1258-1263. DOI： 10.6039/j.issn.1001-0408.2026.10.04.

摘要

目的

基于磷脂酰肌醇3激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白（PI3K/Akt/mTOR）信号通路和多组学技术探讨异绿原酸A抗肝癌的作用机制。

方法

分别考察0（对照组）、0.25、0.5 mg/mL的异绿原酸A干预人肝癌HepG2细胞48 h的侵袭率、迁移率，细胞中含DEP结构域的mTOR相互作用蛋白（DEPTOR）mRNA和mTOR、PI3K、第10号染色体缺失的磷酸酶及张力蛋白同源物（PTEN）蛋白表达量以及Akt蛋白磷酸化水平。采用液相色谱-串联质谱法进行代谢组学检测，筛选差异代谢物并进行京都基因与基因组百科全书（KEGG）通路富集分析；采用RNA测序进行转录组学检测，筛选差异表达基因并进行基因本体（GO）功能注释及KEGG通路富集分析。

结果

与对照组比较，0.25、0.5 mg/mL异绿原酸A干预48 h能显著抑制HepG2细胞侵袭率和迁移率，显著上调DEPTOR mRNA和PTEN蛋白表达量，显著下调PI3K蛋白表达量和Akt蛋白磷酸化水平（0.25 mg/mL异绿原酸A除外）（

＜0.05）。多组学分析共筛选出304个差异代谢物、212个差异表达基因；KEGG通路富集分析提示，异绿原酸A主要通过抑制PI3K/Akt信号通路，协同mTOR信号通路、铁死亡及磷酸戊糖途径、嘌呤/嘧啶代谢等代谢重编程过程，对HepG2细胞生长关键信号进行调控。

结论

异绿原酸A的抗肝癌作用与阻断PI3K/Akt/mTOR信号通路异常激活相关，此外还可能与抑制磷酸戊糖途径及嘌呤/嘧啶代谢、诱导铁死亡等相关。

Abstract

OBJECTIVE

To investigate the mechanism of isochlorogenic acid A against hepatocellular carcinoma based on the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin （PI3K/Akt/mTOR） signaling pathway and multi-omics technology.

METHODS

The invasion rate and migration rate of human hepatocellular carcinoma HepG2 cells after 48 h of intervention with 0 （control group）， 0.25 and 0.5 mg/mL isochlorogenic acid A were examined； mRNA expression of DEP domain-containing mTOR-interacting protein （DEPTOR）， the protein expressions of mTOR， PI3K and phosphatase and tensin homologue deleted on chromosome ten （PTEN）， as well as the phosphorylation level of Akt protein were determined in the cells. Metabolomics analysis was performed using liquid chromatography-tandem mass spectrometry， and differential metabolites were screened and subjected to Kyoto Encyclopedia of Genes and Genomes （KEGG） pathway enrichment analysis； transcriptomics monitoring was conducted by RNA sequencing， and differentially expressed genes were screened and subjected to gene ontology （GO） and KEGG pathway enrichment analyses.

RESULTS

Compared with the control group， intervention with 0.25 and 0.5 mg/mL isochlorogenic acid A for 48 h significantly inhibited the invasion rate and migration rate of HepG2 cells， significantly up-regulated the mRNA expression of DEPTOR and the protein expression of PTEN， and significantly down-regulated the protein expression of PI3K and the phosphorylation level of Akt protein （except for 0.25 mg/mL isochlorogenic acid A）（

＜0.05）. A total of 304 differential metabolites and 212 differentially expressed genes were screened by multi-omics analysis. KEGG pathway enrichment analysis suggested that isochlorogenic acid A regulated key signaling of HepG2 cell growth mainly by inhibiting the PI3K/Akt signaling pathway， synergizing with metabolic reprogramming such as mTOR signaling pathway， ferroptosis， pentose phosphate pathway and purine/pyrimidine metabo

lism.

CONCLUSIONS

The anti-hepatocellular carcinoma effect of isochlorogenic acid A is associated with the blockade of abnormal activation of the PI3K/Akt/mTOR signaling pathway. In addition， it may also be related to the inhibition of the pentose phosphate pathway and purine/pyrimidine metabolism， as well as the induction of ferroptosis，etc.

关键词

Keywords

references

FOGLIA B ， TURATO C ， CANNITO S . Hepatocellular carcinoma：latest research in pathogenesis，detection and treatment [J ] . Int J Mol Sci ， 2023 ， 24 （ 15 ）： 12224 - 12226 .

ZHOU H Y ， SONG T Q . Conversion therapy and maintenance therapy for primary hepatocellular carcinoma [J ] . Biosci Trends ， 2021 ， 15 （ 3 ）： 155 - 160 .

MYINT K Z ， WU K ， XIA Y M ， et al . Polyphenols from Stevia rebaudiana （Bertoni）leaves and their functional properties [J ] . J Food Sci ， 2020 ， 85 （ 2 ）： 240 - 248 .

WANG W B ， XU X W ， ZHAO L ， et al . 3，5-diCQA suppresses colorectal cancer cell growth through ROS/AMPK/mTOR mediated mitochondrial dysfunction and ferroptosis [J ] . Cell Cycle ， 2023 ， 22 （ 18 ）： 1951 - 1968 .

PANG Y L ， LIN Y S ， WANG X Q ， et al . Inhibition of abnormally activated HIF-1α-GLUT1/3-glycolysis pathway enhances the sensitivity of hepatocellular carcinoma to 5-caffeoylquinic acid and its derivatives [J ] . Eur J Pharmacol ， 2022 ， 920 ： 174844 .

HE Y ， SUN M M ， ZHANG G G ， et al . Targeting PI3K/Akt signal transduction for cancer therapy [J ] . Signal Transduct Target Ther ， 2021 ， 6 ： 425 .

TIAN L Y ， SMIT D J ， JÜCKER M . The role of PI3K/Akt/mTOR signaling in hepatocellular carcinoma metabolism [J ] . Int J Mol Sci ， 2023 ， 24 （ 3 ）： 2652 .

DIMRI M ， SATYANARAYANA A . Molecular signaling pathways and therapeutic targets in hepatocellular carcinoma [J ] . Cancers ， 2020 ， 12 （ 2 ）： 491 - 509 .

李瑞梅，李雨晨，杨芳，等 . 蟾毒灵通过抑制PI3K/Akt信号通路治疗肝细胞癌 [J ] . 中国药理学通报， 2026 ， 42 （ 3 ）： 452 - 460 .

LIU Y ， FENG Y ， LI Y X ， et al . Chlorogenic acid decreases malignant characteristics of hepatocellular carcinoma cells by inhibiting DNMT1 expression [J ] . Front Pharmacol ， 2020 ， 11 ： 867 .

RAHMANI F ， ZIAEEMEHR A ， SHAHIDSALES S ， et al . Role of regulatory miRNAs of the PI3K/Akt/mTOR signaling in the pathogenesis of hepatocellular carcinoma [J ] . J Cell Physiol ， 2020 ， 235 （ 5 ）： 4146 - 4152 .

MILLER K A ， DEGAN S ， WANG Y Q ， et al . PTEN-regulated PI3K-p110 and Akt isoform plasticity controls metastatic prostate cancer progression [J ] . Oncogene ， 2024 ， 43 （ 1 ）： 22 - 34 .

XU J ， SUN M H ， WANG X ， et al . NFIC activates DEPTOR and blocks mTOR signaling to inhibit glycol-ysis and immune escape in oral squamous cell carcinoma [J ] . Arch Oral Biol ， 2026 ， 181 ： 106442 .

WANG S ， FU J L ， HAO H F ， et al . Metabolic reprogramming by traditional Chinese medicine and its role in effective cancer therapy [J ] . Pharmacol Res ， 2021 ， 170 ： 105728 .

杨蕙华，陈大红，刁文婧，等 . G6PD调控PI3K/Akt信号通路诱导肝癌细胞索拉非尼耐药的机制研究 [J ] . 中国药房， 2022 ， 33 （ 19 ）： 2338 - 2342 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Progress in mechanistic research on traditional Chinese medicine interventions for irritable bowel syndrome with diarrhea based on omics technologies

Mechanisms of Qiaobai cold compress solution in improving acne vulgaris based on transcriptomics and experiment

Research progress on the mechanism of traditional Chinese medicine regulating metabolic reprogramming to improve breast cancer

肝癌患者行经导管肝动脉化疗栓塞术的奥沙利铂剂量研究

HPLC法同时测定小儿感冒颗粒中4种成分的含量

Related Author

GAO Shanxue

MA Jiale

PENG Long

CHEN Jie

ZHAO Ying

XIE Zhenjiang

ZHU Weina

CAO Liangliang

Related Institution

Graduate School， Tianjin University of Traditional Chinese Medicine

Dept. of Gastroenterology， Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

Dept. of Pharmacy， Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine

Medical Experimental Centre， Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine

Jiangsu Provincial Clinical Medical Innovation Center for Anorectal Diseases of Traditional Chinese Medicine， Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine

⁰